1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
enGene Holdings Inc. Warrants

enGene Holdings Inc. Warrants

ENGNW
enGene Holdings Inc. WarrantsUS flagNASDAQ Capital Market
0.23
USD
-0.05
- -
11.78MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
1
Net Income, GAAP
-15
-23
-24
-100
-55
-117
-122
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
10
17
80
233
169
265
LT Debt
- -
3
31
9
24
22
31
Total Equity
- -
- -
-23
72
273
168
282
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-35.03
-59.19
-53.16

Capital Structure

FRC

•

in mil. unless spec.
Jul'25
Oct'25
Jan'26
ST Debt
7
10
3
LT Borrowings
18
15
25
LT Finance Leases
7
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
52
67
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jul'25
Oct'25
Jan'26
Total Current Assets
211
201
289
Cash, Cash Equivalents & STI
202
194
276
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
20
32
25
Payables & Accruals
10
17
16
ST Debt
7
10
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-38.48%
Free Cash Flow
- -
54.81%
104.7%
Net Income, GAAP
- -
87.26%
112.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Ronald H. W. Cooper
Full Time Employees
56
Sector
Healthcare
Industry
Biotechnology
Address
4868 Rue Levy Montreal QC Canada H4S 1Z9
IPO Date
Feb 1, 2022
CIK
0001980845
Website
engene.com
Similar Companies
Poolbeg Pharma PLC (POLB.L)
Financière de Tubize S.A. (TUB.BR)
Cellivery Therapeutics, Inc. (268600.KQ)
Vera Therapeutics, Inc. (VERA)
Bio Preventive Medicine Corp. (6810.TWO)
Sangamo Therapeutics, Inc. (SGMO)
Business
enGene Holdings Inc. is a clinical-stage biotechnology company that develops non-viral genetic medicines for delivery to mucosal tissues and other organs, with a primary focus on urological cancers including non-muscle invasive bladder cancer (NMIBC). The company offers detalimogene voraplasmid (previously EG-70), a non-viral gene therapy monotherapy evaluated in the ongoing pivotal LEGEND Phase 2 trial for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS); and the proprietary DDX (dually derivatized oligochitosan) gene delivery platform, which enables localized, re-dosable delivery of gene cargos such as DNA and RNA to mucosal tissues in the bladder, lung, gastrointestinal tract, and urinary tract. Founded in 1999 and headquartered in Montreal, Quebec, Canada, with U.S. operations in Boston, Massachusetts, enGene Holdings operates through its subsidiary enGene, Inc. and targets patients with high unmet needs in oncology, particularly those unresponsive to standard BCG therapy. Recent developments include a $60 million private placement financing in October 2024 with investors such as Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital, and Venrock Healthcare Capital Partners to support detalimogene development, pre-commercial activities, DDX platform expansion, and operations into 2027; a prior oversubscribed $200 million private placement in February 2024; and the adoption of the 2025 Employee Stock Purchase Plan in June 2025 along with inducement stock option awards.